SYDNEY, AUSTRALIA: Race Oncology Limited introduced that Mr Damian Clarke-Bruce has been appointed Managing Director and Chief Executive Officer, efficient 1 February 2023.
Mr Phil Lynch will return to his prior role as a Non-Executive Director of Race Oncology and can work closely with Mr Clarke-Bruce to make sure a smooth and efficient management transition. Dr Tillett will proceed in his management role as Chief Scientific Officer and Executive Director.
An extensive internal review in 2022 of the commercialisation and partnership alternative provided by Zantrene recognized the necessity for a full-time, extremely skilled executive with global pharma partnership and drug development functionality to advance Race.
Coulter Partners, a specialised worldwide pharma/biotech executive recruitment agency was appointed to identify appropriate candidates. This process, over a multi-month period, included a diligent analysis of functionality and necessities by the Race Board and administration team.
Mr Clarke-Bruce brings deep global expertise in drug commercialisation and portfolio strategy. He has held executive roles in any respect stages of the drug development process, from pre-clinical analysis through to profitable commercial launch.
He has recognized and outlined new markets for pharma assets and has overseen product registration, entry and reimbursement, medical marketing, and commercial sale. He brings an extensive community from inside the pharmaceutical industry, in addition to distinctive relationships with key opinion leaders throughout a number of therapeutic areas, together with oncology, haematology and immunology.
Mr Clarke-Bruce was most recently the Executive Director of Marketing Global/US Commercial Lead in Rare Disease and Head of the Global Launch Leadership Team for Pharming Healthcare Inc, New Jersey.
Damian Clarke-Bruce commented: “I am truly excited to be becoming a member of the team at Race Oncology at a such a pivotal level of their commercial journey. This is a chance to construct on a fantastic platform established by Phil and the team, recognising Phil’s strong stewardship and commercial acumen to date. I look ahead to working with him to ship a seamless transition and ongoing strategic partnership inside the board and prolonged team.
This role enables the alignment of my private ardour for making a distinction to the well being and wellbeing of sufferers inside our global community, to enhancing the alternatives discovered inside scientific and commercial collaboration, whereas delivering worth to analysis and development inside the unmet wants of cancer, a therapeutic space near my heart.
I look ahead to enriching the strategic, operational and efficiency drivers inside Race Oncology to meet the goals of our investors, the ambitions of our scientists and to ship a best-in-class clinical program, whereas unveiling a distinctive worth proposition for the commercial transition of the business.”